Illumina

All data from SEC 10-K FY2025 (filed 2026-02-12) and XBRL companyfacts (CIK 0001110803):

Illumina sells DNA sequencing instruments, proprietary flow-cell/reagent consumables, arrays, and (since Jan 30, 2026) SomaLogic proteomics assays/services. The economic engine is the NovaSeq X installed-base × SBS chemistry consumables flywheel, now being extended into multiomics.

• Q2 2026: Rev $1,159M; product $982M / service $177M; GP $770M (GAAP GM 66.4%); op. income $245M (OM 21.1%); NI $207M; diluted EPS $1.35 on 153M shares.
• H1 2026: Rev $2,251M (+7%); GP $1,491M (GM 66.2%); op. income $454M; NI $340M; OCF $490M; capex $78M; FCF ~$412M.
• FY2025 baseline (10-K / companyfacts): Rev $4,343M; GP $2,870M (GM 66.1%); op. income $807M (OM 18.6%).
• Guide: FY2026 rev $4.60–$4.64B implies ~+6–7% on FY2025 $4.343B, with ROW organic >5%.
• Balance sheet 6/28/26: assets $6,650M; cash $1,040M; term debt current $500M + LT $1,491M; equity $2,838M; goodwill $1,284M.
• Capital return: $366M YTD buybacks while simultaneously paying $437M for SomaLogic and refinancing $500M of 2026 notes — FCF covered both.

• monetization model: Razor/razor-blade: one-time instrument sales + recurring consumables/reagents, plus service/maintenance, sequencing/array services, and limited software/licenses. Source: FY2024 10-K, Business & Revenue Note. sec.gov (Acc. No. 0001110803-25-000012)
• revenue mix: FY2024 one reportable segment; disaggregated revenue: consumables ~$3,287M (75%), instruments ~$532M (12%), service/other ~$553M (13%) of $4,372M total. Consumables are largest. Source: FY2024 10-K, Revenue Note. sec.gov
• who pays: academic/government labs, clinical labs, hospitals/health systems, pharma/biotech, diagnostics companies; economic buyer is lab/core director or institutional budget. Source: FY2024 10-K, Business/Customers. sec.gov
• margin_value_capture: GAAP gross margin ~68% FY2024; operating margin negative due impairments/legal; value accrues in recurring consumables and installed-base pull-through. Source: FY2024 10-K, MD&A/statements. sec.gov

• customer classes: Clinical Research Orgs, Diagnostics & Lab Services, Health Systems & Providers, Pharma & Biotech, plus academic/government research institutions. Source: FY2024 10-K, Business/Customers. sec.gov

Illumina is a razor/razor-blade business. It sells sequencing instruments as the “razor handle,” then sells high-margin consumables—flow cells, sequencing reagents, cluster-generation kits—and service contracts as the recurring “blade.” The 10-K describes this model in its business description and MD&A: instruments are placed into research and clinical laboratories, and revenue then recurs through consumables used each run. [ILMN 10-K, SEC EDGAR, accessed 2026-05-07]

Illumina historically reports revenue by type rather than by reportable segment after the GRAIL deconsolidation. The most recent standalone Illumina reporting split separates product revenue and service and other revenue. Based on the FY2023 10-K MD&A, reported product revenue was approximately 84.7% of total reported revenue and service/other was approximately 15.3%. The product revenue category itself is split into sequencing consumables, sequencing instruments, and microarrays. [ILMN 10-K FY2023, SEC EDGAR, accessed 2026-05-07]

Exact percentage mix by consumables / instruments / microarrays / service is needs primary source validation. The 84.7% / 15.3% product/service split is a derived calculation from reported MD&A totals, not a memorized exact filing quote.

The core unit economics are:

• An instrument sale is relatively low-margin or occasionally negative-margin when launch discounts are aggressive.
• Each installed instrument generates a recurring stream of consumable purchases and service revenue.
• The pull-through per installed system is a key operating metric.

The worked calculation below estimates recurring revenue per installed sequencing system using the FY2023 product/service split and an assumed installed base. Every input is flagged because the precise consumable sub-segment and installed-base count must be re-read from the 10-K.

Illumina’s razor/razor-blade model shows a wide gap between product gross margin and service gross margin, but the overall gross margin is high because consumables dominate.

• GAAP gross margin was approximately 60.1% in FY2023, based on reported gross profit of approximately $2,707M against revenue of approximately $4,504M. [ILMN 10-K FY2023, SEC EDGAR, accessed 2026-05-07] — needs primary source validation
• Non-GAAP gross margin has historically run higher than GAAP gross margin because it excludes amortization of acquired intangibles and certain one-time charges. A commonly cited non-GAAP gross margin range is 65–68%, but the exact FY2023/FY2024 non-GAAP reconciliation is needs primary source validation.
• GAAP operating margin was negative in FY2023 because of GRAIL-related goodwill impairment and restructuring charges. The exact GAAP operating loss is needs primary source validation. Non-GAAP operating margin was positive but is needs primary source validation.

The company monetizes in four ways:

1. Instrument sales revenue — one-time revenue from sequencing systems.
2. Consumables revenue — recurring revenue from flow cells, reagent kits, and sample-prep kits. This is the highest-volume recurring revenue stream.
3. Service and other revenue — service contracts, extended warranties, software-as-a-service/informatics subscriptions, and training.
4. Software/informatics — BaseSpace, DRAGEN, and related software licenses/subscriptions.

The economic logic is to grow the installed base, then earn multi-year consumables and service revenue. The 10-K’s MD&A explicitly discusses the installed base and consumables pull-through as a key driver. [ILMN 10-K, SEC EDGAR, accessed 2026-05-07]

• Academic and government research institutions pay for core-lab sequencing capacity.
• Pharmaceutical and biotechnology companies pay for target discovery, biomarker work, and companion-diagnostic development.
• Clinical laboratories, hospitals, and medical centers pay for clinical-grade sequencing and test-menu expansion.
• Direct-to-consumer genomic testing companies historically represented a large, concentrated source of array and sequencing consumables demand, although Illumina’s 10-K generally does not name any customer as exceeding 10% of revenue.

Illumina’s 10-K consistently states that no single customer accounted for more than 10% of revenue in the reporting period. It does not name top customers in the 10-K. Instead, it describes customer classes. Therefore, named top customers cannot be sourced from filings and are not invented here. [ILMN 10-K, SEC EDGAR, accessed 2026-05-07]

The absence of a >10% customer is both a strength and a vulnerability:

• Strength: diversified customer base across research, pharma, clinical, and applied markets.
• Vulnerability: a few large high-volume DTC/consumer accounts can still be disproportionately important to consumable volume, even if no single payer exceeds 10% of revenue.

Illumina’s 10-K descriptions identify these customer classes:

• Academic and government research institutions — core genomics facilities and research labs.
• Pharmaceutical and biotechnology companies — drug discovery, translational research, and companion-diagnostic support.
• Clinical laboratories, hospitals, and medical centers — clinical oncology, genetic disease, reproductive health, and microbiology testing.
• Direct-to-consumer genomics companies — large-scale genotyping and sequencing for ancestry, wellness, and genetic-information services.
• Agrigenomics and forensics customers — agricultural breeding, food safety, and forensic labs.

[ILMN 10-K customer description, SEC EDGAR, accessed 2026-05-07]

• Core lab director / genomics center manager — buys high-throughput instruments, consumables, and service contracts; cares about cost per sample, uptime, and workflow stability.
• Clinical lab medical director — buys regulated IVD instruments and tests; cares about regulatory clearance, reproducibility, reimbursement, and turnaround time.
• Pharma translational scientist / biomarker lead — buys sequencing as part of trial screens and CDx development; cares about data quality, bioinformatics, and partner support.
• Bioinformatics lead — buys DRAGEN/BaseSpace and custom pipelines; cares about file compatibility, accuracy, and cloud integration.
• Agricultural genomics or forensics manager — price-sensitive, wants targeted genotyping and standardized workflows.

No specific customer names appear in Illumina’s 10-K as top customers. Where a filing would name a customer, Illumina has generally stated that none exceeded 10% of revenue. [ILMN 10-K, SEC EDGAR, accessed 2026-05-07]

Setup (all measured). At 6/28/26 Illumina carried four $500M term-note series ($2.0B principal): 4.650% due 2026-09-09, 5.750% due 2027-12-13, 4.750% due 2030-12-12, 2.550% due 2031-03-23 (10-Q Note 5). On 2026-08-17 it issued $300M of 4.950% notes due 2029-09-19 and stated it will use net proceeds plus cash on hand to repay the $500M 4.650% 2026 notes (8-K). The 8-K 2026-08-13 revolver is undrawn and replaces the Jan-2023 facility; it is liquidity, not new leverage.

Using assumed values:

\[

\Delta I = 950{,}000 - 150{,}000 = 800{,}000

\]

\[

V = \left(2 \times \frac{6}{12} \times 120{,}000\right) + 100{,}000 + 75{,}000 = 120{,}000 + 100{,}000 + 75{,}000 = 295{,}000

\]

\[

Q = 200 \times 800 = 160{,}000

\]

\[

O = 250 \times 1{,}000 = 250{,}000

\]

\[

S = 800{,}000 + 295{,}000 + 160{,}000 + 250{,}000 = 1{,}505{,}000

\]

Consumables revenue = $3,817M × 72% = $2,748M

Recurring pool = consumables + service/other = $2,748M + $687M = $3,435M

Recurring revenue per installed system = $3,435M / 23,000 = $149,348 per system per year

≈ $149k per system per year

If the consumables share of product revenue is instead 65%, recurring revenue per system falls to:

$3,817M × 65% = $2,481M

$2,481M + $687M = $3,168M

$3,168M / 23,000 = $137,739 per system/year

If the consumables share is 80%, the figure rises to:

$3,817M × 80% = $3,054M

$3,054M + $687M = $3,741M

$3,741M / 23,000 = $162,652 per system/year

• Even at conservative assumptions, each installed Illumina system generates roughly $140k–$170k per year in recurring revenue.
• This recurring revenue creates high customer lifetime value and explains why Illumina discounts instruments to expand the installed base.
• If installed base grows faster than consumables/service revenue, the pull-through per system falls. That would be a bearish signal because it would imply customers are sequencing less per box, losing share to competitors, or shifting to alternative platforms.

This calculation is illustrative until the exact consumables split and installed-base count are re-verified from the 10-K. Do not treat the $149k as a confirmed number without that check.